Macrocyclic Peptides That Block Cancer Signaling: Targeting the Grb2 SH2 Domain
A macrocyclic peptide containing a phosphotyrosyl mimetic achieved potent binding to the Grb2 SH2 domain — a critical cancer signaling hub — demonstrating macrocyclic drug design for disrupting cancer growth pathways.
Quick Facts
What This Study Found
A macrocyclic peptide incorporating beta-aminophosphotyrosyl mimetic achieved potent Grb2 SH2 domain binding through conformational restriction, demonstrating macrocyclic drug design for cancer signaling disruption.
Key Numbers
How They Did This
In-vitro study. Macrocyclic peptide designed with phosphotyrosyl mimetic for Grb2 SH2 binding. Binding affinity measured by surface plasmon resonance. Comparison to linear counterparts.
Why This Research Matters
Protein-protein interactions drive cancer but are notoriously difficult drug targets. Macrocyclic peptides can achieve the large binding surfaces needed to disrupt these interactions — a key cancer drug design strategy.
The Bigger Picture
Protein-protein interaction inhibitors are the next frontier in cancer drugs. Macrocyclic peptides can achieve what small molecules cannot — disrupting the large, flat binding surfaces where cancer proteins communicate.
What This Study Doesn't Tell Us
In-vitro binding only. Cell-based activity and in-vivo efficacy not demonstrated. Oral bioavailability of macrocyclic phosphopeptide mimetics is challenging.
Questions This Raises
- ?Can macrocyclic Grb2 inhibitors achieve cell penetration?
- ?Would this approach work for other cancer SH2 domain targets?
- ?Could oral delivery be achieved through further macrocycle optimization?
Trust & Context
- Key Stat:
- Cancer hub targeted Macrocyclic design achieved potent binding to Grb2 SH2 — a cancer signaling hub that conventional small molecules struggle to block
- Evidence Grade:
- Preliminary in-vitro binding evidence demonstrating a viable macrocyclic approach to a challenging cancer drug target.
- Study Age:
- Published in 2003. Macrocyclic drugs targeting protein-protein interactions in cancer have advanced significantly.
- Original Title:
- Utilization of a beta-aminophosphotyrosyl mimetic in the design and synthesis of macrocyclic Grb2 SH2 domain-binding peptides.
- Published In:
- Journal of medicinal chemistry, 46(13), 2621-30 (2003)
- Authors:
- Lee, Kyeong, Zhang, Manchao, Liu, Hongpeng, Yang, Dajun, Burke, Terrence R
- Database ID:
- RPEP-00841
Evidence Hierarchy
Frequently Asked Questions
Why is cancer signaling hard to block with drugs?
Cancer proteins communicate through large, flat surfaces where they touch each other. Small drug molecules can't cover enough surface area. Macrocyclic (ring-shaped) peptides are big enough to block these protein handshakes.
Could this become a cancer drug?
It's an early-stage design proving the concept works. Ring-shaped peptides that block cancer signaling hubs represent a growing class of cancer drug candidates.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-00841APA
Lee, Kyeong; Zhang, Manchao; Liu, Hongpeng; Yang, Dajun; Burke, Terrence R. (2003). Utilization of a beta-aminophosphotyrosyl mimetic in the design and synthesis of macrocyclic Grb2 SH2 domain-binding peptides.. Journal of medicinal chemistry, 46(13), 2621-30.
MLA
Lee, Kyeong, et al. "Utilization of a beta-aminophosphotyrosyl mimetic in the design and synthesis of macrocyclic Grb2 SH2 domain-binding peptides.." Journal of medicinal chemistry, 2003.
RethinkPeptides
RethinkPeptides Research Database. "Utilization of a beta-aminophosphotyrosyl mimetic in the des..." RPEP-00841. Retrieved from https://rethinkpeptides.com/research/lee-2003-utilization-of-a-betaaminophosphotyrosyl
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.